Skip to main content
SpringerLink
Log in

A Role for SERCA Pumps in the Neurobiology of Neuropsychiatric and Neurodegenerative Disorders

  • Chapter
  • First Online:
Calcium Signaling

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1131))

Abstract

Calcium (Ca2+) is a fundamental regulator of cell fate and intracellular Ca2+ homeostasis is crucial for proper function of the nerve cells. Given the complexity of neurons, a constellation of mechanisms finely tunes the intracellular Ca2+ signaling. We are focusing on the sarco/endoplasmic reticulum (SR/ER) calcium (Ca2+)-ATPase (SERCA) pump, an integral ER protein. SERCA’s well established role is to preserve low cytosolic Ca2+ levels ([Ca2+]cyt), by pumping free Ca2+ ions into the ER lumen, utilizing ATP hydrolysis. The SERCA pumps are encoded by three distinct genes, SERCA1-3, resulting in 12 known protein isoforms, with tissue-dependent expression patterns. Despite the well-established structure and function of the SERCA pumps, their role in the central nervous system is not clear yet. Interestingly, SERCA-mediated Ca2+ dyshomeostasis has been associated with neuropathological conditions, such as bipolar disorder, schizophrenia, Parkinson’s disease and Alzheimer’s disease. We summarize here current evidence suggesting a role for SERCA in the neurobiology of neuropsychiatric and neurodegenerative disorders, thus highlighting the importance of this pump in brain physiology and pathophysiology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Brini M et al (2014) Neuronal calcium signaling: function and dysfunction. Cell Mol Life Sci 71(15):2787–2814

    Article  CAS  PubMed  Google Scholar 

  2. Berridge MJ, Lipp P, Bootman MD (2000) The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 1(1):11–21

    Article  CAS  PubMed  Google Scholar 

  3. Orrenius S, Zhivotovsky B, Nicotera P (2003) Regulation of cell death: the calcium–apoptosis link. Nat Rev Mol Cell Biol 4(7):552–565

    Article  CAS  PubMed  Google Scholar 

  4. Berridge MJ, Bootman MD, Roderick HL (2003) Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 4(7):517–529

    Article  CAS  PubMed  Google Scholar 

  5. Zucker RS (1999) Calcium-and activity-dependent synaptic plasticity. Curr Opin Neurobiol 9(3):305–313

    Article  CAS  PubMed  Google Scholar 

  6. Lyons MR, West AE (2011) Mechanisms of specificity in neuronal activity-regulated gene transcription. Prog Neurobiol 94(3):259–295

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Neher E, Sakaba T (2008) Multiple roles of calcium ions in the regulation of neurotransmitter release. Neuron 59(6):861–872

    Article  CAS  PubMed  Google Scholar 

  8. Carafoli E (2003) The calcium-signalling saga: tap water and protein crystals. Nat Rev Mol Cell Biol 4(4):326–332

    Article  CAS  PubMed  Google Scholar 

  9. Green KN et al (2008) SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Gen Physiol 132(2):i1

    Article  PubMed  Google Scholar 

  10. Dahl R (2017) A new target for Parkinson’s disease: small molecule SERCA activator CDN1163 ameliorates dyskinesia in 6-OHDA-lesioned rats. Bioorg Med Chem 25(1):53–57

    Article  CAS  PubMed  Google Scholar 

  11. LaFerla FM (2002) Calcium dyshomeostasis and intracellular signalling in Alzheimer’s disease. Nat Rev Neurosci 3(11):862–872

    Article  CAS  PubMed  Google Scholar 

  12. Bezprozvanny I, Mattson MP (2008) Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease. Trends Neurosci 31(9):454–463

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Earls LR et al (2010) Dysregulation of presynaptic calcium and synaptic plasticity in a mouse model of 22q11 deletion syndrome. J Neurosci 30(47):15843–15855

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Jacobsen NJ et al (1999) ATP2A2 mutations in Darier’s disease and their relationship to neuropsychiatric phenotypes. Hum Mol Genet 8(9):1631–1636

    Article  CAS  PubMed  Google Scholar 

  15. Grienberger C, Konnerth A (2012) Imaging calcium in neurons. Neuron 73(5):862–885

    Article  CAS  PubMed  Google Scholar 

  16. Fucile S (2004) Ca2+ permeability of nicotinic acetylcholine receptors. Cell Calcium 35(1):1–8

    Article  CAS  PubMed  Google Scholar 

  17. Berridge MJ, Bootman MD, Lipp P (1998) Calcium – a life and death signal. Nature 395(6703):645–648

    Article  CAS  PubMed  Google Scholar 

  18. Schwaller B (2010) Cytosolic Ca2+ buffers. Cold Spring Harb Perspect Biol 2(11):a004051

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Vandecaetsbeek I et al (2009) Structural basis for the high Ca2+ affinity of the ubiquitous SERCA2b Ca2+ pump. Proc Natl Acad Sci 106(44):18533–18538

    Article  PubMed  PubMed Central  Google Scholar 

  20. Morth JP et al (2010) A structural overview of the plasma membrane Na+,K+-ATPase and H+-ATPase ion pumps. Nat Rev Mol Cell Biol 12:60

    Article  CAS  Google Scholar 

  21. Toyoshima C (2008) Structural aspects of ion pumping by Ca2+-ATPase of sarcoplasmic reticulum. Arch Biochem Biophys 476(1):3–11

    Article  CAS  PubMed  Google Scholar 

  22. Bublitz M et al (2010) In and out of the cation pumps: P-type ATPase structure revisited. Curr Opin Struct Biol 20(4):431–439

    Article  CAS  PubMed  Google Scholar 

  23. Bobe R et al (2005) How many Ca2+ ATPase isoforms are expressed in a cell type? A growing family of membrane proteins illustrated by studies in platelets. Platelets 16(3–4):133–150

    Article  CAS  PubMed  Google Scholar 

  24. Dode L et al (2003) Dissection of the functional differences between sarco (endo) plasmic reticulum Ca2+-ATPase (SERCA) 1 and 2 isoforms and characterization of Darier disease (SERCA2) mutants by steady-state and transient kinetic analyses. J Biol Chem 278: 47877–47889

    Article  CAS  PubMed  Google Scholar 

  25. Dode L et al (2002) Dissection of the functional differences between sarco (endo) plasmic reticulum Ca2+-ATPase (SERCA) 1 and 3 isoforms by steady-state and transient kinetic analyses. J Biol Chem 277(47):45579–45591

    Article  CAS  PubMed  Google Scholar 

  26. Britzolaki A et al (2018) The SERCA2: a gatekeeper of neuronal calcium homeostasis in the brain. Cell Mol Neurobiol 38:981–994

    Article  CAS  PubMed  Google Scholar 

  27. Lytton J, MacLennan DH (1988) Molecular cloning of cDNAs from human kidney coding for two alternatively spliced products of the cardiac Ca2+-ATPase gene. J Biol Chem 263(29):15024–15031

    CAS  PubMed  Google Scholar 

  28. Lytton J et al (1992) Functional comparisons between isoforms of the sarcoplasmic or endoplasmic reticulum family of calcium pumps. J Biol Chem 267(20):14483–14489

    CAS  PubMed  Google Scholar 

  29. MacLennan DH et al (1985) Amino-acid sequence of a Ca2+ + Mg2+−dependent ATPase from rabbit muscle sarcoplasmic reticulum, deduced from its complementary DNA sequence. Nature 316(6030):696–700

    Article  CAS  PubMed  Google Scholar 

  30. Dally S et al (2010) Multiple and diverse coexpression, location, and regulation of additional SERCA2 and SERCA3 isoforms in nonfailing and failing human heart. J Mol Cell Cardiol 48(4):633–644

    Article  CAS  PubMed  Google Scholar 

  31. Dally S et al (2006) Ca2+-ATPases in non-failing and failing heart: evidence for a novel cardiac sarco/endoplasmic reticulum Ca2+-ATPase 2 isoform (SERCA2c). Biochem J 395(2):249–258

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. MacLennan DH (1970) Purification and properties of an adenosine triphosphatase from sarcoplasmic reticulum. J Biol Chem 245(17):4508–4518

    CAS  PubMed  Google Scholar 

  33. Toyoshima C, Inesi G (2004) Structural basis of ion pumping by Ca2+-ATPase of the sarcoplasmic reticulum. Annu Rev Biochem 73:269–292

    Article  CAS  PubMed  Google Scholar 

  34. Toyoshima C et al (2000) Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 Å resolution. Nature 405(6787):647–655

    Article  CAS  PubMed  Google Scholar 

  35. Abu-Abed M et al (2002) Characterization of the ATP-binding domain of the sarco (endo) plasmic reticulum Ca2+-ATPase: probing nucleotide binding by multidimensional NMR. Biochemistry 41(4):1156–1164

    Article  CAS  PubMed  Google Scholar 

  36. Toyoshima C, Nomura H (2002) Structural changes in the calcium pump accompanying the dissociation of calcium. Nature 418(6898):605–611

    Article  CAS  PubMed  Google Scholar 

  37. Smolin N, Robia SL (2015) A structural mechanism for calcium transporter headpiece closure. J Phys Chem B 119(4):1407–1415

    Article  CAS  PubMed  Google Scholar 

  38. Brini M, Carafoli E, Cali T (2017) The plasma membrane calcium pumps: focus on the role in (neuro)pathology. Biochem Biophys Res Commun 483(4):1116–1124

    Article  CAS  PubMed  Google Scholar 

  39. Møller JV et al (2005) The structural basis for coupling of Ca2+ transport to ATP hydrolysis by the sarcoplasmic reticulum Ca2+-ATPase. J Bioenerg Biomembr 37(6):359–364

    Article  CAS  PubMed  Google Scholar 

  40. Guerini D (1998) The Ca2+ pumps and the Na+/Ca2+ exchangers. Biometals 11(4):319–330

    Article  CAS  PubMed  Google Scholar 

  41. Zhang P et al (1998) Structure of the calcium pump from sarcoplasmic reticulum at 8-A resolution. Nature 392(6678):835–839

    Article  CAS  PubMed  Google Scholar 

  42. Gelebart P et al (2003) Identification of a new SERCA2 splice variant regulated during monocytic differentiation. Biochem Biophys Res Commun 303(2):676–684

    Article  CAS  PubMed  Google Scholar 

  43. Gunteski-Hamblin AM, Greeb J, Shull GE (1988) A novel Ca2+ pump expressed in brain, kidney, and stomach is encoded by an alternative transcript of the slow-twitch muscle sarcoplasmic reticulum Ca-ATPase gene. Identification of cDNAs encoding Ca2+ and other cation-transporting ATPases using an oligonucleotide probe derived from the ATP-binding site. J Biol Chem 263(29):15032–15040

    CAS  PubMed  Google Scholar 

  44. Lytton J et al (1989) Molecular cloning of the mammalian smooth muscle sarco(endo)plasmic reticulum Ca2+-ATPase. J Biol Chem 264(12):7059–7065

    CAS  PubMed  Google Scholar 

  45. Zarain-Herzberg A, MacLennan D, Periasamy M (1990) Characterization of rabbit cardiac sarco (endo) plasmic reticulum Ca2 (+)-ATPase gene. J Biol Chem 265(8):4670–4677

    CAS  PubMed  Google Scholar 

  46. Brandl CJ et al (1986) Two Ca2+ ATPase genes: homologies and mechanistic implications of deduced amino acid sequences. Cell 44(4):597–607

    Article  CAS  PubMed  Google Scholar 

  47. Dally S et al (2009) Multiple and diverse coexpression, location, and regulation of additional SERCA2 and SERCA3 isoforms in nonfailing and failing human heart. J Mol Cell Cardiol 48:633–644

    Article  CAS  PubMed  Google Scholar 

  48. Periasamy M, Kalyanasundaram A (2007) SERCA pump isoforms: their role in calcium transport and disease. Muscle Nerve 35(4):430–442

    Article  CAS  PubMed  Google Scholar 

  49. Hao L, Rigaud J-L, Inesi G (1994) Ca2+/H+ countertransport and electrogenicity in proteoliposomes containing erythrocyte plasma membrane Ca-ATPase and exogenous lipids. J Biol Chem 269(19):14268–14275

    CAS  PubMed  Google Scholar 

  50. Yu X et al (1993) H+ countertransport and electrogenicity of the sarcoplasmic reticulum Ca2+ pump in reconstituted proteoliposomes. Biophys J 64(4):1232–1242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Salvador JM et al (1998) Ca2+ transport by reconstituted synaptosomal ATPase is associated with H+ countertransport and net charge displacement. J Biol Chem 273(29):18230–18234

    Article  CAS  PubMed  Google Scholar 

  52. Brini M, Carafoli E (2009) Calcium pumps in health and disease. Physiol Rev 89(4):1341–1378

    Article  CAS  PubMed  Google Scholar 

  53. Hasselbach W, Makinose M (1961) The calcium pump of the “relaxing granules” of muscle and its dependence on ATP-splitting. Biochem Z 333:518–528

    CAS  PubMed  Google Scholar 

  54. Lee C-H et al (2002) Ca2+ oscillations, gradients, and homeostasis in vascular smooth muscle. Am J Phys Heart Circ Phys 282(5):H1571–H1583

    CAS  Google Scholar 

  55. Dyla M et al (2018) Dynamics of P-type ATPase transport cycle revealed by single-molecule FRET. Biophys J 114(3):559a

    Article  Google Scholar 

  56. Carafoli E, Brini M (2000) Calcium pumps: structural basis for and mechanism of calcium transmembrane transport. Curr Opin Chem Biol 4(2):152–161

    Article  CAS  PubMed  Google Scholar 

  57. Olesen C et al (2004) Dephosphorylation of the calcium pump coupled to counterion occlusion. Science 306(5705):2251–2255

    Article  CAS  PubMed  Google Scholar 

  58. Mueller B et al (2004) SERCA structural dynamics induced by ATP and calcium. Biochemistry 43(40):12846–12854

    Article  CAS  PubMed  Google Scholar 

  59. Verboomen H et al (1994) The functional importance of the extreme C-terminal tail in the gene 2 organellar Ca2+-transport ATPase (SERCA2a/b). Biochem J 303(Pt 3):979–984

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Martin V et al (2002) Three novel Sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 3 isoforms expression, regulation, and function of the members of the SERCA3 family. J Biol Chem 277(27):24442–24452

    Article  CAS  PubMed  Google Scholar 

  61. Bobe R et al (2004) Identification, expression, function, and localization of a novel (sixth) isoform of the human sarco/endoplasmic reticulum Ca2+ ATPase 3 gene. J Biol Chem 279(23):24297–24306

    Article  CAS  PubMed  Google Scholar 

  62. Brandl CJ et al (1987) Adult forms of the Ca2+ATPase of sarcoplasmic reticulum. Expression in developing skeletal muscle. J Biol Chem 262(8):3768–3774

    CAS  PubMed  Google Scholar 

  63. Korczak B et al (1988) Structure of the rabbit fast-twitch skeletal muscle Ca2+-ATPase gene. J Biol Chem 263(10):4813–4819

    CAS  PubMed  Google Scholar 

  64. Burk SE et al (1989) cDNA cloning, functional expression, and mRNA tissue distribution of a third organellar Ca2+ pump. J Biol Chem 264(31):18561–18568

    CAS  PubMed  Google Scholar 

  65. Wu KD et al (1995) Localization and quantification of endoplasmic reticulum ca(2+)-ATPase isoform transcripts. Am J Phys 269(3 Pt 1):C775–C784

    Article  CAS  Google Scholar 

  66. Wuytack F et al (1989) Smooth muscle expresses a cardiac/slow muscle isoform of the Ca2+−transport ATPase in its endoplasmic reticulum. Biochem J 257(1):117–123

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Lompre A-M et al (1989) Characterization and expression of the rat heart sarcoplasmic reticulum Ca2+-ATPase mRNA. FEBS Lett 249(1):35–41

    Article  CAS  PubMed  Google Scholar 

  68. Kimura T et al (2005) Altered mRNA splicing of the skeletal muscle ryanodine receptor and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase in myotonic dystrophy type 1. Hum Mol Genet 14(15):2189–2200

    Article  CAS  PubMed  Google Scholar 

  69. Miller KK et al (1991) Localization of an endoplasmic reticulum calcium ATPase mRNA in rat brain by in situ hybridization. Neuroscience 43(1):1–9

    Article  CAS  PubMed  Google Scholar 

  70. Sepulveda MR, Hidalgo-Sanchez M, Mata AM (2004) Localization of endoplasmic reticulum and plasma membrane Ca2+-ATPases in subcellular fractions and sections of pig cerebellum. Eur J Neurosci 19(3):542–551

    Article  PubMed  Google Scholar 

  71. Baba-Aissa F et al (1996) Distribution of the organellar Ca2+ transport ATPase SERCA2 isoforms in the cat brain. Brain Res 743(1–2):141–153

    Article  CAS  PubMed  Google Scholar 

  72. Campbell AM, Wuytack F, Fambrough DM (1993) Differential distribution of the alternative forms of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase, SERCA2b and SERCA2a, in the avian brain. Brain Res 605(1):67–76

    Article  CAS  PubMed  Google Scholar 

  73. Plessers L et al (1991) A study of the organellar Ca2(+)-transport ATPase isozymes in pig cerebellar Purkinje neurons. J Neurosci 11(3):650–656

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Morita M, Kudo Y (2010) Growth factors upregulate astrocyte [Ca2+]i oscillation by increasing SERCA2b expression. Glia 58(16):1988–1995

    Article  PubMed  Google Scholar 

  75. Salvador JM et al (2001) Distribution of the intracellular Ca2+-ATPase isoform 2b in pig brain subcellular fractions and cross-reaction with a monoclonal antibody raised against the enzyme isoform. J Biochem 129(4):621–626

    Article  CAS  PubMed  Google Scholar 

  76. Dode L et al (1996) cDNA cloning, expression and chromosomal localization of the human sarco/endoplasmic reticulum Ca (2)-ATPase 3 gene. Biochem J 318(2):689–699

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Wuytack F et al (1994) A sarco/endoplasmic reticulum Ca2+-ATPase 3-type Ca2+ pump is expressed in platelets, in lymphoid cells, and in mast cells. J Biol Chem 269(2):1410–1416

    CAS  PubMed  Google Scholar 

  78. KOVÁCS T et al (2001) All three splice variants of the human sarco/endoplasmic reticulum Ca2+-ATPase 3 gene are translated to proteins: a study of their co-expression in platelets and lymphoid cells. Biochem J 358(3):559–568

    Article  PubMed  PubMed Central  Google Scholar 

  79. Ait-Ghezali L et al (2014) Loss of endoplasmic reticulum calcium pump expression in choroid plexus tumours. Neuropathol Appl Neurobiol 40(6):726–735

    Article  CAS  PubMed  Google Scholar 

  80. Pottorf W et al (2001) Function of SERCA mediated calcium uptake and expression of SERCA3 in cerebral cortex from young and old rats. Brain Res 914(1–2):57–65

    Article  CAS  PubMed  Google Scholar 

  81. Baba-Aïssa F et al (1996) Purkinje neurons express the SERCA3 isoform of the organellar type Ca2+−transport ATPase. Mol Brain Res 41(1–2):169–174

    Article  PubMed  Google Scholar 

  82. Kessler RC et al (2007) Age of onset of mental disorders: a review of recent literature. Curr Opin Psychiatry 20(4):359–364

    Article  PubMed  PubMed Central  Google Scholar 

  83. Kessler RC et al (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62(6):593–602

    Article  PubMed  Google Scholar 

  84. Murray CJ, Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 349(9063):1436–1442

    Article  CAS  PubMed  Google Scholar 

  85. Murray CJ, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990–2020: global burden of disease study. Lancet 349(9064):1498–1504

    Article  CAS  PubMed  Google Scholar 

  86. Whiteford HA et al (2013) Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. Lancet 382(9904):1575–1586

    Article  PubMed  Google Scholar 

  87. Ohi K et al (2017) Cognitive clustering in schizophrenia patients, their first-degree relatives and healthy subjects is associated with anterior cingulate cortex volume. NeuroImage Clin 16:248–256

    Article  PubMed  PubMed Central  Google Scholar 

  88. Purcell S, International Schizophrenia Consortium, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF, Sklar P (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460:748–752

    Article  CAS  PubMed  Google Scholar 

  89. Grunze H (2015) Bipolar disorder. In: Neurobiology of brain disorders. Elsevier, pp 655–673

    Google Scholar 

  90. Miller S et al (2016) Mixed depression in bipolar disorder: prevalence rate and clinical correlates during naturalistic follow-up in the Stanley bipolar network. Am J Psychiatr 173(10):1015–1023

    Article  PubMed  Google Scholar 

  91. Allardyce J et al (2018) Association between schizophrenia-related polygenic liability and the occurrence and level of mood-incongruent psychotic symptoms in bipolar disorder. JAMA Psychiat 75(1):28–35

    Article  Google Scholar 

  92. Jimerson DC et al (1979) CSF calcium: clinical correlates in affective illness and schizophrenia. Biol Psychiatry 14:37–51

    CAS  PubMed  Google Scholar 

  93. Lidow MS (2003) Calcium signaling dysfunction in schizophrenia: a unifying approach. Brain Res Rev 43(1):70–84

    Article  CAS  PubMed  Google Scholar 

  94. Lajtha A, Tettamanti G, Goracci G (2009) Handbook of neurochemistry and molecular neurobiology. Springer, New York

    Book  Google Scholar 

  95. Hertzberg L, Domany E (2018) Commentary: Integration of gene expression and GWAS results supports involvement of calcium signaling in Schizophrenia. J Ment Health Clin Psychol 2(3):5–7

    Article  Google Scholar 

  96. Woon PS et al (2017) CACNA1C genomewide supported psychosis genetic variation affects cortical brain white matter integrity in Chinese patients with schizophrenia. J Clin Psychiatry 75(11):e1284–e1290

    Article  Google Scholar 

  97. Dubovsky SL et al (1991) Elevated platelet intracellular calcium concentration in bipolar depression. Biol Psychiatry 29(5):441–450

    Article  CAS  PubMed  Google Scholar 

  98. Kusumi I, Koyama T, Yamashita I (1992) Thrombin-induced platelet calcium mobilization is enhanced in bipolar disorders. Biol Psychiatry 32(8):731–734

    Article  CAS  PubMed  Google Scholar 

  99. Kusumi I, Koyama T, Yamashita I (1994) Serotonin-induced platelet intracellular calcium mobilization in depressed patients. Psychopharmacology 113(3–4):322–327

    Article  CAS  PubMed  Google Scholar 

  100. Suzuki K et al (2003) Altered 5-HT-induced calcium response in the presence of staurosporine in blood platelets from bipolar disorder patients. Neuropsychopharmacology 28(6):1210–1214

    Article  CAS  PubMed  Google Scholar 

  101. Suzuki K et al (2004) Effects of lithium and valproate on agonist-induced platelet intracellular calcium mobilization: relevance to myosin light chain kinase. Prog Neuro-Psychopharmacol Biol Psychiatry 28(1):67–72

    Article  CAS  Google Scholar 

  102. Suzuki K et al (2001) Serotonin-induced platelet intracellular calcium mobilization in various psychiatric disorders: is it specific to bipolar disorder? J Affect Disord 64(2–3):291–296

    Article  CAS  PubMed  Google Scholar 

  103. Manji HK, Moore GJ, Chen G (2000) Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic–depressive illness. Biol Psychiatry 48(8):740–754

    Article  CAS  PubMed  Google Scholar 

  104. Chen G et al (1999) The mood-stabilizing agents Lithium and valproate RobustlIncrease the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 72(2):879–882

    Article  CAS  PubMed  Google Scholar 

  105. Chen R-W, Chuang D-M (1999) Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression A prominent role in neuroprotection against excitotoxicity. J Biol Chem 274(10):6039–6042

    Article  CAS  PubMed  Google Scholar 

  106. Manji HK et al (1996) Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. J Clin Psychiatry 57:34–46. discussion 47-8

    CAS  PubMed  Google Scholar 

  107. Manji HK, Moore GJ, Chen G (1999) Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 46(7):929–940

    Article  CAS  PubMed  Google Scholar 

  108. Manji HK, Moore GJ, Chen G (2000) Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 61:82–96

    CAS  PubMed  Google Scholar 

  109. Wang J-F, Bown C, Young LT (1999) Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78. Mol Pharmacol 55(3):521–527

    CAS  PubMed  Google Scholar 

  110. Bhat S et al (2012) CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Prog Neurobiol 99(1):1–14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Gonzalez S et al (2013) Suggestive evidence for association between L-type voltage-gated calcium channel (CACNA1C) gene haplotypes and bipolar disorder in Latinos: a family-based association study. Bipolar Disord 15(2):206–214

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Isaac C, Januel D (2016) Neural correlates of cognitive improvements following cognitive remediation in schizophrenia: a systematic review of randomized trials. Socioaffect Neurosci Psychol 6(1):30054

    Article  PubMed  Google Scholar 

  113. Li W et al (2018) A molecule-based genetic association approach implicates a range of voltage-gated calcium channels associated with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 177(4):454–467

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Schizophrenia Working Group of the Psychiatric Genomics, C et al (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511:421–427

    Article  CAS  Google Scholar 

  115. Li Z et al (2017) Genome-wide association analysis identifies 30 new susceptibility loci for schizophrenia. Nat Genet 49(11):1576–1583

    Article  CAS  PubMed  Google Scholar 

  116. Ferreira MAR et al (2008) Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 40(9):1056–1058

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Sklar P et al (2011) Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 43(10):977–983

    Article  CAS  PubMed Central  Google Scholar 

  118. Lencz T, Malhotra A (2015) Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. Mol Psychiatry 20(7):820–826

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Craddock N et al (1994) Familial cosegregation of major affective disorder and Darier's disease (keratosis follicularis). Br J Psychiatry 164(3):355–358

    Article  CAS  PubMed  Google Scholar 

  120. Burge SM, Wilkinson JD (1992) Darier-white disease: a review of the clinical features in 163 patients. J Am Acad Dermatol 27(1):40–50

    Article  CAS  PubMed  Google Scholar 

  121. Ringpfeil F et al (2001) Darier disease--novel mutations in ATP2A2 and genotype-phenotype correlation. Exp Dermatol 10(1):19–27

    Article  CAS  PubMed  Google Scholar 

  122. Judge M, McLean W, Munro C (2010) Disorders of keratinization. In: Rook’s textbook of dermatology, vol 1, pp 1–122

    Google Scholar 

  123. Munro C (1992) The phenotype of Darier's disease: penetrance and expressivity in adults and children. Br J Dermatol 127(2):126–130

    Article  CAS  PubMed  Google Scholar 

  124. Nellen RGL et al (2017) Mendelian disorders of cornification caused by defects in intracellular calcium pumps: mutation update and database for variants in ATP2A2 and ATP2C1 associated with Darier disease and Hailey–Hailey disease. Hum Mutat 38(4):343–356

    Article  CAS  PubMed  Google Scholar 

  125. Green EK et al (2013) Novel ATP2A2 mutations in a large sample of individuals with D arier disease. J Dermatol 40(4):259–266

    Article  CAS  PubMed  Google Scholar 

  126. Sakuntabhai A et al (1999) Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease. Nat Genet 21(3):271–277

    Article  CAS  PubMed  Google Scholar 

  127. Ahn W et al (2003) Multiple effects of SERCA2b mutations associated with Darier's disease. J Biol Chem 278(23):20795–20801

    Article  CAS  PubMed  Google Scholar 

  128. Sato K et al (2004) Distinct types of abnormality in kinetic properties of three Darier disease-causing sarco (endo) plasmic reticulum Ca2+-ATPase mutants that exhibit normal expression and high Ca2+ transport activity. J Biol Chem 279(34):35595–35603

    Article  CAS  PubMed  Google Scholar 

  129. Miyauchi Y et al (2006) Comprehensive analysis of expression and function of 51 sarco (endo) plasmic reticulum Ca2+-ATPase mutants associated with Darier disease. J Biol Chem 281(32):22882–22895

    Article  CAS  PubMed  Google Scholar 

  130. Foggia L et al (2006) Activity of the hSPCA1 Golgi Ca2+ pump is essential for Ca2+−mediated Ca2+ response and cell viability in Darier disease. J Cell Sci 119(4):671–679

    Article  CAS  PubMed  Google Scholar 

  131. Leinonen P et al (2005) Keratinocytes cultured from patients with Hailey–Hailey disease and Darier disease display distinct patterns of calcium regulation. Br J Dermatol 153(1):113–117

    Article  CAS  PubMed  Google Scholar 

  132. Hetz C (2012) The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol 13(2):89–102

    Article  CAS  PubMed  Google Scholar 

  133. Savignac M et al (2014) SERCA2 dysfunction in Darier disease causes endoplasmic reticulum stress and impaired cell-to-cell adhesion strength: rescue by Miglustat. J Investig Dermatol 134(7):1961–1970

    Article  CAS  PubMed  Google Scholar 

  134. Celli A et al (2011) Endoplasmic reticulum Ca2+ depletion activates XBP1 and controls terminal differentiation in keratinocytes and epidermis. Br J Dermatol 164(1):16–25

    Article  CAS  PubMed  Google Scholar 

  135. Engin B et al (2015) Darier disease: a fold (intertriginous) dermatosis. Clin Dermatol 33(4):448–451

    Article  PubMed  Google Scholar 

  136. Suryawanshi H et al (2017) Darier disease: a rare genodermatosis. J Oral Maxillofac Pathol 21(2):321–321

    PubMed  PubMed Central  Google Scholar 

  137. Cheour M et al (2009) Darier’s disease: an evaluation of its neuropsychiatric component. Encéphale 35(1):32–35

    Article  CAS  PubMed  Google Scholar 

  138. Wang SL et al (2002) Darier’s disease associated with bipolar affective disorder: a case report. Kaohsiung J Med Sci 18(12):622–626

    PubMed  Google Scholar 

  139. Gordon-Smith K et al (2010) The neuropsychiatric phenotype in Darier disease. Br J Dermatol 163(3):515–522

    Article  CAS  PubMed  Google Scholar 

  140. Jones I et al (2002) Evidence for familial cosegregation of major affective disorder and genetic markers flanking the gene for Darier’s disease. Mol Psychiatry 7(4):424–427

    Article  CAS  PubMed  Google Scholar 

  141. Cederlöf M et al (2015) The association between Darier disease, bipolar disorder, and schizophrenia revisited: a population-based family study. Bipolar Disord 17(3):340–344

    Article  CAS  PubMed  Google Scholar 

  142. Cederlöf M et al (2015) Intellectual disability and cognitive ability in Darier disease: Swedish nation-wide study. Br J Dermatol 173(1):155–158

    Article  CAS  PubMed  Google Scholar 

  143. Dodiuk-Gad R et al (2016) Darier disease in Israel: combined evaluation of genetic and neuropsychiatric aspects. Br J Dermatol 174(3):562–568

    Article  CAS  PubMed  Google Scholar 

  144. Baba-Aissa F et al (1998) Distribution and isoform diversity of the organellar Ca2+ pumps in the brain. Mol Chem Neuropathol 33(3):199–208

    Article  CAS  PubMed  Google Scholar 

  145. Takeichi T et al (2016) Darier’s disease complicated by schizophrenia caused by a novel ATP2A2 mutation. Acta Derm Venereol 96(7):993–994

    Article  PubMed  Google Scholar 

  146. Nakamura T et al (2016) Loss of function mutations in ATP2A2 and psychoses: a case report and literature survey. Psychiatry Clin Neurosci 70(8):342–350

    Article  CAS  PubMed  Google Scholar 

  147. Noda K et al (2016) Novel and recurrent ATP2A2 mutations in Japanese patients with Darier’s disease. Nagoya J Med Sci 78(4):485–492

    PubMed  PubMed Central  Google Scholar 

  148. Hough C et al (1999) Elevated basal and thapsigargin-stimulated intracellular calcium of platelets and lymphocytes from bipolar affective disorder patients measured by a fluorometric microassay. Biol Psychiatry 46(2):247–255

    Article  CAS  PubMed  Google Scholar 

  149. Scambler PJ (2000) The 22q11 deletion syndromes. Hum Mol Genet 9(16):2421–2426

    Article  CAS  PubMed  Google Scholar 

  150. McDonald-McGinn DM et al (2001) Phenotype of the 22q11.2 deletion in individuals identified through an affected relative: cast a wide FISHing net! Genet Med 3(1):23–29

    Article  CAS  PubMed  Google Scholar 

  151. Schreiner MJ et al (2013) Converging levels of analysis on a genomic hotspot for psychosis: insights from 22q11. 2 deletion syndrome. Neuropharmacology 68:157–173

    Article  CAS  PubMed  Google Scholar 

  152. Chun S et al (2014) Specific disruption of thalamic inputs to the auditory cortex in schizophrenia models. Science 344(6188):1178–1182

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. Kobrynski LJ, Sullivan KE (2007) Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet 370(9596):1443–1452

    Article  CAS  PubMed  Google Scholar 

  154. Yagi H et al (2003) Role of TBX1 in human del22q11.2 syndrome. Lancet 362(9393):1366–1373

    Article  CAS  PubMed  Google Scholar 

  155. Papangeli I, Scambler P (2013) The 22q11 deletion: DiGeorge and velocardiofacial syndromes and the role of TBX1. Wiley Interdiscip Rev Dev Biol 2(3):393–403

    Article  CAS  PubMed  Google Scholar 

  156. Devaraju P et al (2017) Haploinsufficiency of the 22q11. 2 microdeletion gene Mrpl40 disrupts short-term synaptic plasticity and working memory through dysregulation of mitochondrial calcium. Mol Psychiatry 22(9):1313–1326

    Article  CAS  PubMed  Google Scholar 

  157. Shi H, Wang Z (2018) Atypical microdeletion in 22q11 deletion syndrome reveals new candidate causative genes: a case report and literature review. Medicine 97(8):e9936

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  158. Ellegood J et al (2014) Neuroanatomical phenotypes in a mouse model of the 22q11.2 microdeletion. Mol Psychiatry 19(1):99–107

    Article  CAS  PubMed  Google Scholar 

  159. Mukai J et al (2015) Molecular substrates of altered axonal growth and brain connectivity in a mouse model of schizophrenia. Neuron 86(3):680–695

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  160. Karpinski BA et al (2014) Dysphagia and disrupted cranial nerve development in a mouse model of DiGeorge (22q11) deletion syndrome. Dis Model Mech 7(2):245–257

    Article  CAS  PubMed  Google Scholar 

  161. Oskarsdottir S, Vujic M, Fasth A (2004) Incidence and prevalence of the 22q11 deletion syndrome: a population-based study in Western Sweden. Arch Dis Child 89(2):148–151

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  162. Chow EW et al (2006) Neurocognitive profile in 22q11 deletion syndrome and schizophrenia. Schizophr Res 87(1):270–278

    Article  PubMed  PubMed Central  Google Scholar 

  163. Pulver AE et al (1994) Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. J Nerv Ment Dis 182(8):476–477

    Article  CAS  PubMed  Google Scholar 

  164. Botto LD et al (2003) A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 112(1 Pt 1):101–107

    Article  PubMed  Google Scholar 

  165. Bassett AS et al (2011) Practical guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr 159(2):332–339.e1

    Article  PubMed  PubMed Central  Google Scholar 

  166. Bearden CE et al (2001) The neurocognitive phenotype of the 22q11. 2 deletion syndrome: selective deficit in visual-spatial memory. J Clin Exp Neuropsychol 23(4):447–464

    Article  CAS  PubMed  Google Scholar 

  167. Eliez S et al (2000) Young children with Velo-cardio-facial syndrome (CATCH-22). Psychological and language phenotypes. Eur Child Adolesc Psychiatry 9(2):109–114

    Article  CAS  PubMed  Google Scholar 

  168. Swillen A et al (2000) Chromosome 22q11 deletion syndrome: update and review of the clinical features, cognitive-behavioral spectrum, and psychiatric complications. Am J Med Genet A 97(2):128–135

    Article  CAS  Google Scholar 

  169. Gothelf D et al (2007) Developmental trajectories of brain structure in adolescents with 22q11. 2 deletion syndrome: a longitudinal study. Schizophr Res 96(1):72–81

    Article  PubMed  PubMed Central  Google Scholar 

  170. Rauch A et al (2006) Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation. Am J Med Genet A 140(19):2063–2074

    Article  PubMed  Google Scholar 

  171. Bassett AS, Chow EW (2008) Schizophrenia and 22q11.2 deletion syndrome. Curr Psychiatry Rep 10(2):148–157

    Article  PubMed  PubMed Central  Google Scholar 

  172. Fung WL et al (2010) Elevated prevalence of generalized anxiety disorder in adults with 22q11.2 deletion syndrome. Am J Psychiatry 167(8):998

    Article  PubMed  PubMed Central  Google Scholar 

  173. Karayiorgou M, Simon TJ, Gogos JA (2010) 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat Rev Neurosci 11:402–416

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  174. Schneider M et al (2014) Psychiatric disorders from childhood to adulthood in 22q11. 2 deletion syndrome: results from the international consortium on brain and behavior in 22q11. 2 deletion syndrome. Am J Psychiatr 171(6):627–639

    Article  PubMed  Google Scholar 

  175. Jonas RK, Montojo CA, Bearden CE (2014) The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan. Biol Psychiatry 75(5):351–360

    Article  CAS  PubMed  Google Scholar 

  176. Green T et al (2009) Psychiatric disorders and intellectual functioning throughout development in velocardiofacial (22q11. 2 deletion) syndrome. J Am Acad Child Adolesc Psychiatry 48(11):1060–1068

    Article  PubMed  Google Scholar 

  177. Bassett AS et al (2003) The schizophrenia phenotype in 22q11 deletion syndrome. Am J Psychiatr 160(9):1580–1586

    Article  PubMed  Google Scholar 

  178. Tang SX et al (2017) The psychosis Spectrum in 22q11.2 deletion syndrome is comparable to that of nondeleted youth. Biol Psychiatry 82(1):17–25

    Article  CAS  PubMed  Google Scholar 

  179. Earls LR et al (2012) Age-dependent microRNA control of synaptic plasticity in 22q11 deletion syndrome and schizophrenia. J Neurosci 32(41):14132–14144

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  180. Earls LR, Zakharenko SS (2014) A synaptic function approach to investigating complex psychiatric diseases. Neuroscientist 20(3):257–271

    Article  CAS  PubMed  Google Scholar 

  181. Schizophrenia_Working_Group_of_the_Psychiatric_Genomics-Consortium (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511(7510):421–427

    Article  CAS  PubMed Central  Google Scholar 

  182. Richard EA et al (2017) Potential synergistic action of 19 schizophrenia risk genes in. Schizophr Res 180:64–69

    Article  PubMed  Google Scholar 

  183. Genis-Mendoza A et al (2018) Comparative analysis of gene expression profiles involved in calcium signaling pathways using the NLVH animal model of schizophrenia. J Mol Neurosci 64(1):111–116

    Article  CAS  PubMed  Google Scholar 

  184. Hagenston AM, Bading H (2011) Calcium signaling in synapse-to-nucleus communication. Cold Spring Harb Perspect Biol:a004564

    Google Scholar 

  185. Lisek M et al (2016) Regional brain dysregulation of Ca2+−handling systems in ketamine-induced rat model of experimental psychosis. Cell Tissue Res 363(3):609–620

    Article  CAS  PubMed  Google Scholar 

  186. Stefani MR, Moghaddam B (2005) Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol Psychiatry 57(4):433–436

    Article  CAS  PubMed  Google Scholar 

  187. Neill JC et al (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 128(3):419–432

    Article  CAS  PubMed  Google Scholar 

  188. Chakrabarti S et al (2015) Metabolic risk factors of sporadic Alzheimer’s disease: implications in the pathology, pathogenesis and treatment. Aging Dis 6(4):282–299

    Article  PubMed  PubMed Central  Google Scholar 

  189. Davie CA (2008) A review of Parkinson’s disease. Br Med Bull 86:109–127

    Article  CAS  PubMed  Google Scholar 

  190. Nussbaum RL, Ellis CE (2003) Alzheimer’s disease and Parkinson’s disease. N Engl J Med 348(14):1356–1364

    Article  CAS  PubMed  Google Scholar 

  191. Warner TT, Schapira AH (2003) Genetic and environmental factors in the cause of Parkinson’s disease. Ann Neurol 53(S3):S16–S25

    Article  CAS  PubMed  Google Scholar 

  192. Cookson MR, Xiromerisiou G, Singleton A (2005) How genetics research in Parkinson’s disease is enhancing understanding of the common idiopathic forms of the disease. Curr Opin Neurol 18(6):706–711

    Article  PubMed  Google Scholar 

  193. Gilks WP et al (2005) A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet 365(9457):415–416

    CAS  PubMed  Google Scholar 

  194. Forno LS (1996) Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 55(3):259–272

    Article  CAS  PubMed  Google Scholar 

  195. Braak H et al (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211

    Article  PubMed  Google Scholar 

  196. Gandhi S, Wood NW (2005) Molecular pathogenesis of Parkinson’s disease. Hum Mol Genet 14(18):2749–2755

    Article  CAS  PubMed  Google Scholar 

  197. Sudo H et al (2001) Secreted Abeta does not mediate neurotoxicity by antibody-stimulated amyloid precursor protein. Biochem Biophys Res Commun 282(2):548–556

    Article  CAS  PubMed  Google Scholar 

  198. Mattson MP (2007) Calcium and neurodegeneration. Aging Cell 6(3):337–350

    Article  CAS  PubMed  Google Scholar 

  199. Mattson MP (2004) Pathways towards and away from Alzheimer’s disease. Nature 430(7000):631–639

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  200. Ganguly G et al (2017) Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer’s disease and Parkinson’s disease. Drug Des Devel Ther 11:797–810

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  201. Xie A et al (2014) Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson’s disease. Biomed Res Int 2014:648740

    PubMed  PubMed Central  Google Scholar 

  202. Bonda DJ et al (2011) The mitochondrial dynamics of Alzheimer’s disease and Parkinson’s disease offer important opportunities for therapeutic intervention. Curr Pharm Des 17(31):3374–3380

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  203. Perier C, Vila M (2012) Mitochondrial biology and Parkinson’s disease. Cold Spring Harb Perspect Med 2(2):a009332

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  204. Sen CK, Packer L (1996) Antioxidant and redox regulation of gene transcription. FASEB J 10(7):709–720

    Article  CAS  PubMed  Google Scholar 

  205. Aiken CT et al (2011) Oxidative stress-mediated regulation of proteasome complexes. Mol Cell Proteomics 10(5):R110.006924

    Article  PubMed  PubMed Central  Google Scholar 

  206. Pajares M et al (2015) Redox control of protein degradation. Redox Biol 6:409–420

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  207. Baillet A et al (2010) The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson’s disease. Neurochem Res 35(10):1530–1537

    Article  CAS  PubMed  Google Scholar 

  208. Zhou C, Huang Y, Przedborski S (2008) Oxidative stress in Parkinson’s disease: a mechanism of pathogenic and therapeutic significance. Ann NY Acad Sci 1147(1):93–104

    Article  CAS  PubMed  Google Scholar 

  209. Protter D, Lang C, Cooper AA (2012) alphaSynuclein and mitochondrial dysfunction: a pathogenic partnership in parkinson’s disease? Parkinsons Dis 2012:829207

    PubMed  PubMed Central  Google Scholar 

  210. Banerjee K et al (2010) Alpha-synuclein induced membrane depolarization and loss of phosphorylation capacity of isolated rat brain mitochondria: implications in Parkinson’s disease. FEBS Lett 584(8):1571–1576

    Article  CAS  PubMed  Google Scholar 

  211. Wang X et al (2009) Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease. J Neurosci 29(28):9090–9103

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  212. Devi L et al (2006) Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction. J Neurosci 26(35):9057–9068

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  213. Mounsey RB, Teismann P (2011) Mitochondrial dysfunction in Parkinson’s disease: pathogenesis and neuroprotection. Parkinson’s Dis 2011

    Google Scholar 

  214. Pacelli C et al (2011) Mitochondrial defect and PGC-1α dysfunction in parkin-associated familial Parkinson’s disease. Biochim Biophys Acta (BBA) - Mol Basis Dis 1812(8):1041–1053

    Article  CAS  Google Scholar 

  215. Wen Y et al (2011) Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem, 2011:jbc. M110. 208447

    Google Scholar 

  216. Stutzmann GE, Mattson MP (2011) Endoplasmic reticulum Ca2+ handling in excitable cells in health and disease. Pharmacol Rev:pr. 110.003814

    Google Scholar 

  217. Woods NK, Padmanabhan J (2012) Neuronal calcium signaling and Alzheimer’s disease. In: Islam MS (ed) Calcium signaling. Springer Netherlands, Dordrecht, pp 1193–1217

    Chapter  Google Scholar 

  218. Gallego-Sandin S, Alonso MT, Garcia-Sancho J (2011) Calcium homoeostasis modulator 1 (CALHM1) reduces the calcium content of the endoplasmic reticulum (ER) and triggers ER stress. Biochem J 437(3):469–475

    Article  CAS  PubMed  Google Scholar 

  219. Verkhratsky A (2005) Physiology and pathophysiology of the calcium store in the endoplasmic reticulum of neurons. Physiol Rev 85(1):201–279

    Article  CAS  PubMed  Google Scholar 

  220. Verkhratsky A (2002) The endoplasmic reticulum and neuronal calcium signalling. Cell Calcium 32(5–6):393–404

    Article  CAS  PubMed  Google Scholar 

  221. Corona C et al (2011) New therapeutic targets in Alzheimer’s disease: brain deregulation of calcium and zinc. Cell Death Dis 2(6):e176

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  222. Mattson MP (2010) ER calcium and Alzheimer’s disease: in a state of flux. Sci Signal 3(114):pe10–pe10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  223. Magi S et al (2016) Intracellular calcium dysregulation: implications for Alzheimer’s disease. Biomed Res Int 2016:1–14

    Article  CAS  Google Scholar 

  224. Egorova P, Popugaeva E, Bezprozvanny I (2015) Disturbed calcium signaling in spinocerebellar ataxias and Alzheimer’s disease. Semin Cell Dev Biol 40:127–133

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  225. Berridge MJ (2013) Dysregulation of neural calcium signaling in Alzheimer disease, bipolar disorder and schizophrenia. Prion 7(1):2–13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  226. Mattson MP (1990) Antigenic changes similar to those seen in neurofibrillary tangles are elicited by glutamate and Ca2+ influx in cultured hippocampal neurons. Neuron 4(1):105–117

    Article  CAS  PubMed  Google Scholar 

  227. Mattson MP et al (1993) Comparison of the effects of elevated intracellular aluminum and calcium levels on neuronal survival and tau immunoreactivity. Brain Res 602(1):21–31

    Article  CAS  PubMed  Google Scholar 

  228. Kurbatskaya K et al (2016) Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer’s disease brain. Acta Neuropathol Commun 4(1):34

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  229. Mattson MP et al (1992) Beta-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12(2):376–389

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  230. Mattson MP, Tomaselli KJ, Rydel RE (1993) Calcium-destabilizing and neurodegenerative effects of aggregated β-amyloid peptide are attenuated by basic FGF. Brain Res 621(1):35–49

    Article  CAS  PubMed  Google Scholar 

  231. Khachaturian ZS (1989) Calcium, membranes, aging and Alzheimer’s disease: introduction and overview. Ann NY Acad Sci 568(1):1–4

    Article  CAS  PubMed  Google Scholar 

  232. Shankar GM et al (2007) Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27(11):2866–2875

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  233. Thibault O, Gant JC, Landfield PW (2007) Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store. Aging Cell 6(3):307–317

    Article  CAS  PubMed  Google Scholar 

  234. Kamenetz F et al (2003) APP processing and synaptic function. Neuron 37(6):925–937

    Article  CAS  PubMed  Google Scholar 

  235. Cirrito JR et al (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J Neurosci 23(26):8844–8853

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  236. Kuchibhotla KV et al (2008) Aβ plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 59(2):214–225

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  237. Abramov E et al (2009) Amyloid-β as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci 12(12):1567–1576

    Article  CAS  PubMed  Google Scholar 

  238. Surmeier DJ et al (2017) Calcium and Parkinson’s disease. Biochem Biophys Res Commun 483(4):1013–1019

    Article  CAS  PubMed  Google Scholar 

  239. Calì T, Ottolini D, Brini M (2011) Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson’s disease. Biofactors 37(3):228–240

    Article  CAS  PubMed  Google Scholar 

  240. Chan CS, Gertler TS, Surmeier DJ (2009) Calcium homeostasis, selective vulnerability and Parkinson’s disease. Trends Neurosci 32(5):249–256

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  241. Surmeier DJ, Guzman JN, Sanchez-Padilla J (2010) Calcium, cellular aging, and selective neuronal vulnerability in Parkinson’s disease. Cell Calcium 47(2):175–182

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  242. Mosharov EV et al (2009) Interplay between cytosolic dopamine, calcium, and α-synuclein causes selective death of substantia nigra neurons. Neuron 62(2):218–229

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  243. Nedergaard S, Flatman J, Engberg I (1993) Nifedipine-and omega-conotoxin-sensitive Ca2+ conductances in guinea-pig substantia nigra pars compacta neurones. J Physiol 466(1):727–747

    CAS  PubMed  PubMed Central  Google Scholar 

  244. Calì T et al (2013) Enhanced parkin levels favor ER-mitochondria crosstalk and guarantee Ca2+ transfer to sustain cell bioenergetics. Biochim Biophys Acta (BBA) - Mol Basis Dis 1832(4):495–508

    Article  CAS  Google Scholar 

  245. Calì T et al (2012) α-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J Biol Chem 287(22):17914–17929

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  246. Sandebring A et al (2009) Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signalling. FEBS J 276(18):5041–5052

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  247. Nath S et al (2011) Raised calcium promotes α-synuclein aggregate formation. Mol Cell Neurosci 46(2):516–526

    Article  CAS  PubMed  Google Scholar 

  248. Rcom H et al (2014) Interactions between calcium and alpha-Synuclein in neurodegeneration. Biomol Ther 4(3)

    Google Scholar 

  249. Surmeier DJ (2007) Calcium, ageing, and neuronal vulnerability in Parkinson’s disease. Lancet Neurol 6(10):933–938

    Article  CAS  PubMed  Google Scholar 

  250. Danzer KM et al (2007) Different species of α-synuclein oligomers induce calcium influx and seeding. J Neurosci 27(34):9220–9232

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  251. Hettiarachchi NT et al (2009) α-Synuclein modulation of Ca2+ signaling in human neuroblastoma (SH-SY5Y) cells. J Neurochem 111(5):1192–1201

    Article  CAS  PubMed  Google Scholar 

  252. El-Agnaf OM et al (2004) A strategy for designing inhibitors of α-synuclein aggregation and toxicity as a novel treatment for Parkinson’s disease and related disorders. FASEB J 18(11):1315–1317

    Article  CAS  PubMed  Google Scholar 

  253. Rockenstein E et al (2002) Differential neuropathological alterations in transgenic mice expressing α-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68(5):568–578

    Article  CAS  PubMed  Google Scholar 

  254. Vekrellis K et al (2011) Pathological roles of α-synuclein in neurological disorders. Lancet Neurol 10(11):1015–1025

    Article  CAS  PubMed  Google Scholar 

  255. Vekrellis K et al (2009) Inducible over-expression of wild type α-synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death. J Neurochem 109(5):1348–1362

    Article  CAS  PubMed  Google Scholar 

  256. Kragh CL et al (2009) α-Synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem 284(15):10211–10222

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  257. Betzer C et al (2018) Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. EMBO Rep 19:e44617

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  258. Lowe R et al (2004) Calcium (II) selectively induces α-synuclein annular oligomers via interaction with the C-terminal domain. Protein Sci 13(12):3245–3252

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  259. Goodwin J et al (2013) Raised calcium and oxidative stress cooperatively promote alpha-synuclein aggregate formation. Neurochem Int 62(5):703–711

    Article  CAS  PubMed  Google Scholar 

  260. Colla E et al (2012) Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J Neurosci 32(10):3301–3305

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  261. Hurley MJ et al (2013) Parkinson’s disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain 136(7):2077–2097

    Article  PubMed  Google Scholar 

  262. Pasternak B et al (2012) Use of calcium channel blockers and Parkinson’s disease. Am J Epidemiol 175(7):627–635

    Article  PubMed  Google Scholar 

  263. Ritz B et al (2010) L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol 67(5):600–606

    CAS  PubMed  PubMed Central  Google Scholar 

  264. Becker C, Jick SS, Meier CR (2008) Use of antihypertensives and the risk of Parkinson disease. Neurology 70(16 Part 2):1438–1444

    Article  CAS  PubMed  Google Scholar 

  265. Marras C et al (2012) Dihydropyridine calcium channel blockers and the progression of parkinsonism. Ann Neurol 71(3):362–369

    Article  CAS  PubMed  Google Scholar 

  266. Lytton J, Westlin M, Hanley MR (1991) Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biol Chem 266(26):17067–17071

    CAS  PubMed  Google Scholar 

  267. Park SW et al (2010) Sarco (endo) plasmic reticulum Ca2+-ATPase 2b is a major regulator of endoplasmic reticulum stress and glucose homeostasis in obesity. Proc Natl Acad Sci 2010:12044

    Google Scholar 

  268. Kang S et al (2015) Small molecular allosteric activator of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) attenuates diabetes and metabolic disorders. J Biol Chem, 2015:p. jbc. M115. 705012

    Google Scholar 

  269. Tanzi RE et al (1987) Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 235(4791):880–884

    Article  CAS  PubMed  Google Scholar 

  270. Sherrington R et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375(6534):754–760

    Article  CAS  PubMed  Google Scholar 

  271. Levy-Lahad E et al (1995) Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 269(5226):973–977

    Article  CAS  PubMed  Google Scholar 

  272. Rogaev EI et al (1995) Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature 376:775

    Article  CAS  PubMed  Google Scholar 

  273. Cruts M, Theuns J, Van Broeckhoven C (2012) Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat 33(9):1340–1344

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  274. Wolfe MS et al (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 398(6727):513–517

    Article  CAS  PubMed  Google Scholar 

  275. Annaert WG et al (1999) Presenilin 1 controls γ-secretase processing of amyloid precursor protein in pre-Golgi compartments of hippocampal neurons. J Cell Biol 147(2):277–294

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  276. De Strooper B et al (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391(6665):387–390

    Article  CAS  PubMed  Google Scholar 

  277. Jin H et al (2010) Presenilin-1 holoprotein is an interacting partner of sarco endoplasmic reticulum calcium-ATPase and confers resistance to endoplasmic reticulum stress. J Alzheimers Dis 20(1):261–273

    Article  CAS  PubMed  Google Scholar 

  278. Brunello L et al (2009) Presenilin-2 dampens intracellular ca(2+) stores by increasing ca(2+) leakage and reducing ca(2+) uptake. J Cell Mol Med 13(9b):3358–3369

    Article  PubMed  PubMed Central  Google Scholar 

  279. Dreses-Werringloer U et al (2008) A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell 133(7):1149–1161

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  280. Nensa FM et al (2014) Amyloid beta a4 precursor protein-binding family B member 1 (FE65) interactomics revealed synaptic vesicle glycoprotein 2A (SV2A) and sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) as new binding proteins in the human brain. Mol Cell Proteomics 13(2):475–488

    Article  CAS  PubMed  Google Scholar 

  281. Ikin AF et al (2007) A macromolecular complex involving the amyloid precursor protein (APP) and the cytosolic adapter FE65 is a negative regulator of axon branching. Mol Cell Neurosci 35(1):57–63

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  282. Cao X, Südhof TC (2001) A transcriptively active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293(5527):115–120

    Article  CAS  PubMed  Google Scholar 

  283. Pietrzik CU et al (2004) FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J Neurosci 24(17):4259–4265

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  284. Kinoshita A et al (2002) The γ secretase-generated carboxyl-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cells. J Biol Chem 277(32):28530–28536

    Article  CAS  PubMed  Google Scholar 

  285. Santiard-Baron D et al (2005) Expression of human FE65 in amyloid precursor protein transgenic mice is associated with a reduction in β-amyloid load. J Neurochem 93(2):330–338

    Article  CAS  PubMed  Google Scholar 

  286. Krajnak K, Dahl R (2018) A new target for Alzheimer’s disease: a small molecule SERCA activator is neuroprotective in vitro and improves memory and cognition in APP/PS1 mice. Bioorg Med Chem Lett 28(9):1591–1594

    Article  CAS  PubMed  Google Scholar 

  287. Nussbaum RL (2018) Genetics of synucleinopathies. Cold Spring Harb Perspect Med 8(6):a024109

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  288. Lashuel HA et al (2013) The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14(1):38–48

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  289. Ghiglieri V, Calabrese V, Calabresi P (2018) Alpha-Synuclein: from early synaptic dysfunction to neurodegeneration. Front Neurol 9:295

    Article  PubMed  PubMed Central  Google Scholar 

  290. Tuon T et al (2012) Physical training exerts neuroprotective effects in the regulation of neurochemical factors in an animal model of. Neuroscience 227:305–312

    Article  CAS  PubMed  Google Scholar 

  291. Lundblad M et al (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15(1):120–132

    Article  CAS  PubMed  Google Scholar 

  292. Jouve L et al (2010) Deep brain stimulation of the center median–parafascicular complex of the thalamus has efficient anti-parkinsonian action associated with widespread cellular responses in the basal ganglia network in a rat model of Parkinson’s disease. J Neurosci 30(29):9919–9928

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

A.B. was supported by the University of Dayton (UD) Graduate School and by the UD Office for Graduate Affairs through the Graduate Student Summer Fellowship (GSSF) Program. J.S. was supported by a Barry Goldwater Scholarship in Excellence and Education Award, a Biology Department Lancaster-McDougall Award, a CAS Dean Fellowship, the Berry Summer Thesis Institute, and the UD Honors Program. P.M.P. was supported by an inaugural STEM Catalyst grant and Start-up funding from UD, as well as by Research Council Seed Grants (RCSG) from the University of Dayton Research Institute (UDRI); this work was supported by the National Institute Of Neurological Disorders and Stroke of the National Institutes of Health under award number R03NS109836 (to P.M.P.). Funding sponsors had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Conflict of Interest None.

Author information

Authors and Affiliations

  1. Department of Biology & Center for Tissue Regeneration and Engineering at Dayton (TREND), University of Dayton, Dayton, OH, USA

    Aikaterini Britzolaki, Joseph Saurine, Benjamin Klocke & Pothitos M. Pitychoutis

Authors
  1. Aikaterini Britzolaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph Saurine
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Benjamin Klocke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pothitos M. Pitychoutis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pothitos M. Pitychoutis .

Editor information

Editors and Affiliations

  1. Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden

    Md. Shahidul Islam

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Britzolaki, A., Saurine, J., Klocke, B., Pitychoutis, P.M. (2020). A Role for SERCA Pumps in the Neurobiology of Neuropsychiatric and Neurodegenerative Disorders. In: Islam, M. (eds) Calcium Signaling. Advances in Experimental Medicine and Biology, vol 1131. Springer, Cham. https://doi.org/10.1007/978-3-030-12457-1_6

Download citation

Publish with us

Policies and ethics

Search

Navigation